No, Science Does Not Indicate that HPV Vaccines Can Eradicate Cervical Cancer

Misinformation is ramping up. It's bait and switch due to type replacement. Here is what the science actually says.

By James Lyons-Weiler, PhD Popular Rationalism

When Public Health Narratives Outpace Scientific Reality

For over a decade, a confident public health slogan has circulated: HPV vaccination will eradicate cervical cancer. It is repeated in press releases, amplified in global campaigns, and presented to the public as a scientific inevitability.

But eradication is not a slogan. It is a population-level outcome that must be demonstrated, replicated, and observable in long-term epidemiological data—not predicted by models or inferred from surrogate markers. And you cannot get there by reporting “look, no vaccine-targeted type-related CIN2+!”. Because OTHER, non-vaccine-targeted type CIN2+ fill the gap. That’s called Type Replacement, and CDC and Merck has been aware of this for sometime.

The United Kingdom, with one of the most robust cancer-registration systems in the world, provides real-world test of the eradication hypothesis. And its population-level trends do not merely fail to confirm eradication—they directly contradict the central claims.

This article analyzes the evidence without fear or favor, integrating ecological dynamics, trial methodology, and international HPV surveillance. It also incorporates the legitimate benefits of HPV vaccines while correcting the record on what science can and cannot yet support.

The Eradication Narrative: A Promise Issued Decades Before Evidence Could Exist

The idea that HPV vaccines could eliminate cervical cancer emerged primarily from modeling studies, not clinical or population-level outcomes.

• Global projections of elimination were based on mathematical assumptions (Bruni et al., 2016, Lancet Global Health, PMID: 27090780).

• These models treated short-term reductions in HPV16/18 infections as if they automatically translated into long-term cancer prevention.

• Yet the natural history of cervical cancer spans 20–40 years, not the 3–5 years of clinical HPV-vaccine trials (McCredie et al., 2008, Lancet Oncology, PMID: 18586173).

Public health agencies promoted eradication long before any vaccinated birth cohort reached the age at which invasive cervical cancer typically manifests. This was not evidence-based messaging—it was speculation.

The United Kingdom: A Real-World Test—and It Does Not Support Eradication

England’s national cancer registry provides the strongest dataset currently available to evaluate whether HPV vaccination influences invasive cervical cancer in young cohorts.

1. Invasive cervical cancer rose sharply in the first vaccinated cohorts

• Ages 20–24 (85% vaccinated): incidence rose from 2.7 to 4.6 per 100,000 between 2012 and 2014—a 70% increase (Castanon et al., 2018, J Med Screen, PMID: 29247658).

• Ages 25–29 (catch‑up vaccinated): incidence doubled from ~11 to ~22 per 100,000 between 2007 and 2015 (ONS cancer-registration statistics).

2. These increases are cohort-specific

Older unvaccinated women did not experience similar increases. If screening changes were responsible, the rise would appear across age groups. It does not.

3. The increase was in invasive cancer, not CIN

Adjusted screening algorithms typically elevate detection of precancerous lesions, not invasive tumors.

4. No decline in overall cervical cancer despite a decade of high uptake

If eradication were underway, incidence should fall at the national level. It has not.

Conclusion: The UK data offer no support for eradication. Instead, they reveal trends that demand scientific re-evaluation.

The Trials: What They Showed, What They Didn’t, and Why This Matters

1. Trials did not show prevention of invasive cervical cancer

As Miller summarized (2020, Clin Oncol (R Coll Radiol), PMID: 32758313), no HPV vaccine trial demonstrated a reduction in invasive cervical cancer. Surrogate endpoints were used instead.

2. Surrogate endpoints were inflated

Rees et al. (2020, BMJ Evid Based Med, PMID: 31831533) documented that: - Trials used CIN1+ composites, inflating perceived efficacy. - CIN1 comprises lesions with near-zero predictive value for cancer. - Short testing intervals exaggerated “persistent infection.”

3. Harms were underreported

Jørgensen et al. (2018, Syst Rev, PMID: 30064455) found: - Active adjuvants used as “placebos.” - Truncated harms reporting. - Exclusion of participants potentially experiencing adverse reactions.

These issues matter profoundly because eradication claims rely on trial data extrapolated decades into the future. If the foundational endpoints are weak or inflated, so is the eradication narrative.

HPV Is an Evolving, Multi-Type Ecological System—not a Static Target

1. The eradication narrative assumes a static viral ecosystem

Yet HPV is a competitive ecological system containing 15+ carcinogenic types (Muñoz et al., 2003, NEJM, PMID: 12867664).

2. Removing dominant types creates ecological opportunity for others

This is classic evolutionary ecology. When dominant types (e.g., 16 and 18) are suppressed, non-vaccine high-risk types fill the ecological niche.

3. Post-vaccine ecological shifts are now documented internationally

• United Kingdom: Shifts in non-vaccine high-risk HPV (Mesher et al., 2016, Emerg Infect Dis, PMID: 27648506).

• Finland: Increases in HPV52 and HPV58 (Gray et al., 2019, Int J Cancer, PMID: 30719706).

• Netherlands: Rise in HPV56 and HPV52 (Hoes et al., 2020, Clin Infect Dis, PMID: 33249475).

• Japan: HPV58 increased from 0.65% to 2.17% (Sekine et al., 2020, Vaccines, PMID: 32751198).

• Italy: High-risk non-vaccine types prevalent in young women (Giambi et al., 2013, BMC Infect Dis, PMID: 23497228).

• United States: Vaccinated women showed higher rates of non-vaccine high-risk HPV (Guo et al., 2015, AACR Abstract 844).

These shifts contradict WHO and CDC messaging that type replacement is “not occurring.” The empirical record indicates the opposite.

Addressing the 9‑Valent Vaccine: Why It Does Not Resolve the Problem

Critics often respond, “But the 9-valent vaccine covers seven high-risk types.”

Why this does not solve the ecological issue:

1. More than 15 oncogenic types circulate globally (Muñoz et al., 2003).

2. Replacement is already occurring in types not covered by 9vHPV (52, 56, 58, 68, 73, etc.), some of which are oncogenic. Rare types are likely more deadly; that is why they are rare.

3. The earliest UK increases occurred before 9vHPV rollout, meaning these rises cannot be attributed to gaps in coverage.

4. Broader coverage increases ecological pressure, potentially accelerating replacement (as seen in pneumococcal serotype dynamics).

5. Population-level eradication requires removal of all carcinogenic types, not half.

The 9-valent vaccine may provide broader protection, but it does not change the mathematical or ecological impossibility of “eradication” in a multi-type viral ecosystem.

The Lie in the Result: Reduction in Vaccine‑Targeted Type‑Association CIN2+

A recurring construction in the HPV‑vaccine literature reports a clean zero for lesions attributed to vaccine genotypes—“no HPV16/18‑related CIN2+,” “no vaccine‑type high‑grade cervical disease,” or “no HPV6/11/16/18‑related CIN/EGL”—and that phrasing is then generalized in downstream communications as if it established an absence of precancer. It does not. These statements are type‑conditioned endpoints confined to vaccine genotypes within a specific analytic window; they do not measure total CIN2+/HSIL. When read precisely, they certify only that within the cohort, period, and attribution rules used, no lesions were linked to the vaccine types, while leaving all non‑vaccine high‑risk types—and any lesions they cause—outside the frame. PubMed

The Nordic long‑term follow‑ups of the quadrivalent program are the clearest examples. The twelve‑year Clin Infect Dis report states there were “no breakthrough cases of HPV16/18 CIN2+,” and the final fourteen‑year EClinicalMedicine analysis repeats the finding as “no cases of HPV16/18‑related high‑grade cervical dysplasia” in the per‑protocol effectiveness population. Both results are genotype‑restricted by design; neither is a claim that CIN2+ vanished as a disease class. (PMID: 29029053; DOI: 10.1093/cid/cix797. PMID: 32637895; DOI: 10.1016/j.eclinm.2020.100401.) PubMed

The Costa Rica Vaccine Trial’s eleven‑year report on the bivalent vaccine is routinely paraphrased as if it demonstrated eradication of precancer in vaccinees, yet the paper explicitly reports zero only for HPV16/18‑associated endpoints: at year eleven, none of 1,913 vaccinated women developed HPV16/18‑associated CIN2+, while 34 of 2,233 unvaccinated women did. That is the correct, narrow reading of the zero; it is not evidence that all‑type CIN2+ disappeared in the vaccinated arm. (PMID: 33271093; DOI: 10.1016/S1470‑2045(20)30524‑6.) Cancer Epidemiology & Genetics

Adult cohorts replicate the same rhetorical shape. The FUTURE III long‑term extension in women aged 27–45 reports “no breakthrough cases of CIN or genital warts related to HPV6/11/16/18 for up to 10 years,” again a vaccine‑type endpoint, not a census of all lesions. The independent Colombian extension following adult women likewise states, “There were no cases of HPV6/11/16/18‑related CIN or EGL during the extended follow‑up,” which is accurate within its endpoint definition while silent on non‑vaccine‑type disease. (PMID: 35853188; DOI: 10.1080/21645515.2022.2052700. PMID: 24391768; DOI: 10.1371/journal.pone.0083431.) PMC

When investigators genotype high‑grade lesions in vaccinated populations, the residual burden is dominated by non‑vaccine types—often explicitly with zero for 16/18. In Finland, vaccinated women with HSIL had no HPV16/18 HSIL cases observed; the leading genotypes were 52, 59/51/58, and 33, demonstrating lesion biology outside the vaccine spectrum. (PMID: 38801336; DOI: 10.1002/ijc.35044.) Wiley Online Library

Population pathology in Scotland shows the same pattern at scale: among more than 1,700 CIN2/3 cases in women under 25, detection of 16/18 fell sharply with vaccination while the relative contribution from non‑established high‑risk—and even low‑risk—types was greater in vaccinated women with CIN2+ than in unvaccinated women, i.e., the disease burden persists with a shifted genotype mix rather than disappearing. (PMID: 37563221; DOI: 10.1038/s41416‑023‑02386‑9.) PubMed

U.S. HPV‑IMPACT surveillance resolves the same distinction in incidence terms. After vaccine introduction, HPV16‑CIN2+ and HPV18‑CIN2+ fell steeply among screened women aged 20–24, while, among women aged 25–29, CIN2+ attributed to seven non‑vaccine types increased significantly. That is precisely what the type‑restricted zeros omit and precisely what determines whether total precancer is declining or merely changing composition. (PMID: 35904861; DOI: 10.1002/ijc.34231.) PubMed

Even within the Costa Rica program that reports “no vaccine‑type CIN2+” in a later window, the companion Lancet Oncology analysis documents precancers caused by non‑vaccine‑preventable types in vaccinated women and explicitly frames this as clinical unmasking. Taken together, these results confirm that “no vaccine‑type CIN2+” is an attribution statement, not a claim about the absence of CIN2+/HSIL as such. (PMID: 35709811; DOI: 10.1016/S1470‑2045(22)00291‑1.) PubMed

The only scientifically honest way to present these zeros is alongside the contemporaneous count and composition of non‑vaccine‑type CIN2+/HSIL. The trial and surveillance record already shows that when vaccine‑type attribution goes to zero, non‑vaccine high‑risk types occupy the remaining burden; the endpoint label is doing the work, not eradication.

Why the Screening-Change Explanation Fails Scientifically

Public health authorities have repeatedly argued that increases in invasive cancer are artifacts of screening changes.

This explanation is incompatible with the evidence.

1. Only vaccinated cohorts show increases

A genuine screening artifact would appear across all age groups.

2. The increases were in invasive cancers, not lesions

Screening changes increase detection of CIN, not invasive tumors.

3. Older women (who underwent the same screening system) showed no increase

This completely undermines the screening hypothesis.

4. Stage distribution contradicted the screening narrative

The rise was in early-stage invasive cancers, not pre-cancers—a pattern incompatible with shifts in screening invitations.

The “screening explanation” is a rhetorical maneuver, not a scientific one.

The Consequences of Premature Scientific Certainty

Overconfident eradication claims create misaligned incentives: - Journals suppress contradictory analyses. - Policymakers treat model outputs as evidence. - Researchers who question ecological assumptions face institutional hostility. - Public trust erodes when real-world data diverge from official promises.

Jørgensen et al. (2018) also documented involvement of CDC officials in Cochrane processes reviewing HPV vaccines—showing how institutional entanglement can shape scientific messaging.

Toward a Scientifically Honest Framework

A rational assessment acknowledges:

- HPV vaccines reduce infections of targeted types.

- They have not yet demonstrated reductions in invasive cervical cancer.

- Type replacement is empirically real.

- Multi-type ecosystems require long-term ecological surveillance.

- Eradication models must be revised to incorporate real-world constraints.

No scientific field should treat marketing language as epidemiological truth.

Critical Analysis of Recent Misleading Studies on HPV Type Replacement and Behavior-Driven Confounding

Recent publications from 2022–2025 have been widely cited as evidence that HPV vaccination does not lead to type replacement or altered HPV ecology. However, close inspection of methodology reveals that many of these studies employ structural biases—particularly the misuse of behavioral adjustments—that effectively erase the very ecological signals they purport to evaluate. The studies often rely on STI clinic populations, chlamydia-positive cohorts, and other high-force transmission settings that mask differences in viral ecology. Several papers adjust for chlamydia positivity or number of sexual partners—variables that are not independent confounders but mediators altered by vaccination messaging itself, introducing collider bias and obscuring replacement dynamics.

For example, analyses of residual swabs from chlamydia-screening programs (Checchi et al., 2023; Lewis et al., 2022) adjust for chlamydia infection as a proxy for promiscuity. Yet vaccine recipients, perceiving themselves as protected, may engage in riskier sexual behavior—an effect supported by the Guo study showing increased sexual activity in vaccinated women. When authors adjust for these sexually transmitted infections, they mathematically remove the ecological and behavioral pathway through which non-vaccine HPV types expand. This results in a built-in methodological guarantee of “no replacement detected,” irrespective of the underlying biology.

Moreover, several studies report “stable” prevalence of non-vaccine high-risk HPV types despite dramatic declines in HPV16/18. In ecological terms, stability under dominant-type suppression is itself evidence of relative replacement, as non-vaccine types fill the newly opened niche. Meanwhile, independent international studies—uninvolved with national health agencies or vaccine manufacturers—consistently document increasing prevalence of HPV52, HPV56, HPV58, HPV68, HPV39, HPV51, and others, along with growing HPV α-diversity following vaccination. Notably, recent attempts to reclassify type replacement as “clinical unmasking” (Tota et al., 2025) constitute rhetorical reframing rather than empirical disproof.

The cumulative evidence from unbiased studies shows clear patterns of ecological competition, replacement, and behavioral feedback loops—findings that national surveillance bodies and industry-linked researchers repeatedly obscure through overadjustment, selective framing, and methodological opacity. Any honest assessment of HPV vaccination impacts must incorporate these ecological realities.

Conclusion: Reality Is the Final Arbiter

Science makes progress by confronting evidence—not by amplifying hopeful narratives.

The real-world data from the United Kingdom, combined with international findings of type replacement and the limitations of surrogate endpoints, demonstrate that eradication is not supported by current evidence. Public health must adapt its messaging to reality, not force reality to conform to messaging.

Cervical cancer eradication remains a theoretical possibility, but it is not a demonstrated outcome, nor a scientifically justified promise. Responsible science requires acknowledging uncertainty and following the evidence wherever it leads.

This is not only a matter of scientific rigor—it is a matter of public trust.

References

1. Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016 Apr;4(7):e453–e463. PMID: 27090780.

2. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008 May;9(5):425-434. PMID: 18586173.

3. Markowitz LE, Liu G, Hariri S, et al. Prevalence of HPV After Introduction of the Vaccination Program in the United States. J Infect Dis. 2016 Dec 15;213(11):1911–1919. PMID: 27805771.

4. Simms KT, Smith MA, Lew JB, et al. Impact of HPV vaccination on cervical cancer elimination: a mechanistic modeling study. Lancet Public Health. 2016 Nov;2(1):e19–e28. PMID: 29241766.

5. Castanon A, Landy R, Sasieni P. Is cervical screening in young women justified? J Med Screen. 2018 Mar;25(1):51–57. PMID: 29247658.

6. Office for National Statistics (ONS). Cervical Cancer Registration Statistics, England: 2007–2015. London: ONS.

7. Miller D. What can we expect from HPV vaccination? Clin Oncol (R Coll Radiol). 2020 Sep;32(9):e145–e154. PMID: 32758313.

8. Rees CP, Bruni L, Eltoum IA, et al. Assessing HPV vaccine impact on cervical precancer: issues of endpoint definition. BMJ Evid Based Med. 2020 Jun;25(3):73–79. PMID: 31831533.

9. Jørgensen L, Gøtzsche PC, Jefferson T. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias. Syst Rev. 2018 Jul 26;7(1):231. PMID: 30064455.

10. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518–527. PMID: 12867664.

11. Mesher D, Soldan K, Howell-Jones R, et al. Population-level effects of HPV vaccination on nonvaccine-type infections: England 2008–2016. Emerg Infect Dis. 2016 Oct;22(10):1732–1740. PMID: 27648506.

12. Gray P, Luostarinen T, Vänskä S, et al. Occurrence of HPV type replacement up to 9 years after vaccination. Int J Cancer. 2019 Aug 1;145(3):785–796. PMID: 30719706.

13. Hoes J, Woestenberg PJ, Bogaards JA, et al. Population impact of girls-only HPV vaccination: cross-protective and second-order herd effects. Clin Infect Dis. 2020 Nov 28;ciaa1770. PMID: 33249475. https://pubmed.ncbi.nlm.nih.gov/33249475/

14. Sekine M, Yamaguchi M, Kudo R, et al. Epidemiological profile of HPV infection after vaccination initiation in Japan. Vaccines (Basel). 2020 Jul 29;8(3):425. PMID: 32751198.

15. Giambi C, Donati S, Carozzi F, et al. High-risk HPV prevalence and type distribution in Italian women aged 18–26. BMC Infect Dis. 2013 Feb 20;13:74. PMID: 23497228.

16. Guo F, Cofie LE, Berenson AB. Cervical HPV infection in vaccinated vs unvaccinated young women. AACR Proceedings. 2015 Abstract 844.

17. Guo, F., Hirth, J. M., & Berenson, A. B. (2015). Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20–26 years). Human Vaccines & Immunotherapeutics, 11(10), 2337–2344. https://doi.org/10.1080/21645515.2015.1066948

18. Bowden SJ, Ellis LB, Kyrgiou M, et al. High prevalence of HPV51 in unvaccinated women: implications for type replacement. Vaccines (Basel). 2022 Oct 20;10(10):1754. PMID: 36298619.

19. Lewis RM, Naleway AL, Klein NP, et al. Cytology and HPV-type changes among 20–24-year-olds post-vaccination. J Low Genit Tract Dis. 2022 Apr 1;26(2):135–139. PMID: 35316258.

20. Checchi M, Mesher D, Panwar K, et al. HPV type-specific trends in sexually active young women in England after 10 years of vaccination. Vaccine. 2023 Oct 26;41(45):6734–6744. PMID: 37821315.

21. Gargano JW, McClung N, Lewis RM, et al. HPV type-specific trends in cervical precancers in the U.S. 2008–2016. Int J Cancer. 2023 Jan 15;152(2):137–150. PMID: 35904861.

22. Pimenoff VN, Gray P, Louvanto K, et al. Ecological diversity of non-vaccine HPV types after community vaccination. Cell Host Microbe. 2023 Nov 8;31(11):1921–1929.e3. PMID: 37944494.

23. Su Y, Zheng T, Bi Z, et al. Patterns of multiple HPV infection and type competition in Chinese women. Hum Vaccin Immunother. 2024 Dec;20(1):2334474. PMID: 38619081.

24. Hampson IN, Oliver AW. Updated review of HPV vaccine effects on type prevalence and cervical pathology. Viruses. 2024 Aug 2;16(8):1245. PMID: 39205218.

25. Cameron RL, Palmer TJ, Cuschieri K, et al. Scotland’s approach to monitoring real-world HPV vaccine effectiveness. Vaccine. 2024 Aug 30;42(21):126177. PMID: 39128198.

26. Kusters JMA, Schim van der Loeff MF, Heijne JCM, et al. Type-specific HPV prevalence during 12 years of bivalent vaccination in the Netherlands. J Infect Dis. 2025 Feb 4;231(1):e165–e176. PMID: 39271142.

27. Chen Y, Li Q, Du L, et al. Epidemiologic evaluation of HPV type competition in unvaccinated Chinese women. Front Microbiol. 2025 Apr 4;16:1546166. PMID: 40256626.

28. Brewer SK, Lewis RM, Querec TD, et al. Evaluation of Possible HPV type replacement after vaccine introduction by race/ethnicity. Vaccine. 2025 Aug 30;62:127576. PMID: 40865244. https://pubmed.ncbi.nlm.nih.gov/40865244/